Targeted Ferrocene Products as Inductors of Apoptosis in Cancer Cells - Mwafi, Nesrin;Wlassoff, Wjasschesslaw
32,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
  • Broschiertes Buch

Cancerous cells are persistently exposed to more oxidative stress than adjacent normal cells as a result of abnormal regulation of some enzymes. Consequently, excessive amounts of hydrogen peroxide are accumulated in tumour cells. Iron-containing compounds, such as ferrocene, can react with hydrogen peroxide through Fenton reaction where highly reactive hydroxyl radicals are formed. These radicals possess a damaging effect on the DNA of the cancer cells, thereby inducing the apoptosis and inhibiting cancerous cell growth. Ferrocene on its own has no affinity for tumour cells and if…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Cancerous cells are persistently exposed to more oxidative stress than adjacent normal cells as a result of abnormal regulation of some enzymes. Consequently, excessive amounts of hydrogen peroxide are accumulated in tumour cells. Iron-containing compounds, such as ferrocene, can react with hydrogen peroxide through Fenton reaction where highly reactive hydroxyl radicals are formed. These radicals possess a damaging effect on the DNA of the cancer cells, thereby inducing the apoptosis and inhibiting cancerous cell growth. Ferrocene on its own has no affinity for tumour cells and if administered as it is, it will not be specifically delivered to these targets. This book outlines a simple approach for targeting the ferrocene via conjugation with nucleoside. The ferrocene-linked nucleosides are supposed to be preferentially taken up by actively dividing cancerous cells where they are phosphorylated intracellularly into the corresponding nucleotides. These nucleotides will then become incorporated into the cellular DNA. This is advantageous as the radicals will be generated near the DNA, thus making the damage more significant.
Autorenporträt
received her BSc in Pharmacy from the University of Jordan and MSc in Pharmacology and Biotechnology from Sheffield Hallam University, UK. She was awarded her university Prize as the best MSc student in 2007 and the German DAAD PhD scholarship in 2010. Her research interest is in developing new therapeutic approaches for Cancer treatment.